The U.S. Food and Drug Administration (FDA) has cleared contrast developer Bracco Diagnostics' Lumason agent for use in ultrasound of the urinary tract in pediatric patients.
The procedure is indicated to evaluate suspected or known vesicoureteral reflux, a urinary tract abnormality in newborns, infants, and children. It offers an alternative to current procedures, which expose children to radiation, Bracco said.
